Cardiovascular Devices are used in treating diseases related to the heart and the circulatory system. Percutaneous Transluminal Coronary Angioplasty (PTCA) is a intervention that helps restore blood flow to the blocked coronary artery without the requirement of open-heart surgery. GlobalData uses proprietary data and analytics to provide a comprehensive report on the ptca balloon catheters devices market, including market shares of different players within Australia. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the ptca balloon catheters market in Australia was Boston Scientific followed by B. Braun Melsungen, Shockwave Medical, Medtronic, Terumo, Microport Scientific, Koninklijke Philips, Biotronik SE, Teleflex, Meril Life Sciences, OrbusNeich and Abbott Laboratories.
In this intervention, a balloon at the end of a catheter is expanded to open the blocked coronary artery by compressing the plaque. Types of PTCA Balloon Catheters include PTCA Standard Balloon Catheters, Cutting and Scoring Balloon Catheters and PTCA Drug Coated Balloon (DCB) Catheters. Cutting and Scoring Balloon Catheters have microsurgical blades mounted longitudinally on the angioplasty balloon catheter. PTCA Standard Balloon Catheters are coronary catheters equipped with a balloon capable of expanding. A PTCA DCB Catheter is an anti-restenotic drug coated PTCA balloon catheter intended to prevent re-narrowing of the coronary arteries.
The value of the ptca balloon catheters devices market within Australia was expected to be over $10m in 2023.
For the latest complete market share analysis of ptca balloon catheters device market in Australia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.